Equillium Inc., a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced an expansion of its financial strategy to include a cryptocurrency treasury reserve. This move aims to diversify its assets, enhance liquidity, and potentially increase long-term capital appreciation. CEO Bruce Steel stated that following a comprehensive assessment, the board has determined this strategy aligns with stockholders' interests. The company plans to provide further updates on the strategy by the third quarter of 2025. Concurrently, Equillium remains committed to advancing its biotech mission, particularly the clinical development of EQ504, its aryl hydrocarbon receptor modulator. As of mid-2025, the company reported having $11.5 million in cash and expects to be funded into the fourth quarter of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。